Accelerate Diagnostics price target lowered to $2 from $5 at Craig-Hallum

Craig-Hallum analyst Alex Novak lowered the firm’s price target on Accelerate Diagnostics (AXDX) to $2 from $5 and keeps a Hold rating on the shares. The firm notes Q4 was another challenged quarter for the company. Accelerate has still not seen any of the Becton Dickinson (BDX) partnership progress convert into meaningful revenue, Craig-Hallum adds.